CM
TMDX icon

Castleark Management’s Transmedics TMDX Stock Holding History

Castleark Management’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-49,170
Closed -$7.72M – 330
2024
Q3 		$7.72M Buy
49,170
+6,270
+15% +$966K 0.31% 68
2024
Q2 		$6.46M Buy
+42,900
New +$5.15M 0.26% 82
2023
Q3 		– Sell
-132,535
Closed -$11.1M – 314
2023
Q2 		$11.1M Buy
132,535
+1,260
+1% +$96.5K 0.5% 37
2023
Q1 		$9.94M Hold
131,275
– – 0.49% 37
2022
Q4 		$8.1M Buy
131,275
+13,030
+11% +$693K 0.42% 52
2022
Q3 		$4.94M Buy
+118,245
New +$5.14M 0.27% 88

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Castleark Management's TMDX Position: Q4 2024 in Review

Castleark Management sold out of Transmedics (TMDX) in Q4 2024, closing a stake of 49,170 shares — an estimated $7.72M sold.

Castleark Management first reported a position in TMDX in Q3 2022 and held it in 6 quarters. The position peaked at $11.1M in Q2 2023. 315 funds tracked by Wall St. Rank hold TMDX as of Q4 2024.

  • Castleark Management reported no remaining Transmedics position as of Q4 2024 after selling out during the quarter.
  • Castleark Management sold 49,170 Transmedics shares in Q4 2024, an estimated $7.72M.
  • Castleark Management first reported a position in Transmedics in Q3 2022 and held it in 6 quarters.
  • Castleark Management's Transmedics position peaked at $11.1M in Q2 2023.
  • 315 funds tracked by Wall St. Rank held Transmedics as of Q4 2024.

Based on Castleark Management's 13F filing for Q4 2024, filed 18 Feb 2025.